{"generated":"2026-10-26T07:14:53.678Z","patches":[{"id":"nct04996875","kind":"trial","name":"(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis","route":"/trials/nct04996875/","field":"status","current":"recruiting","proposed":"active","reason":"Primary completion date 2025-09-19 has passed (actual) and the registry status is RECRUITING","source":"https://clinicaltrials.gov/study/NCT04996875","registryValue":"RECRUITING; primary completion 2025-09-19","proposedOn":"2026-10-26"},{"id":"nct05208047","kind":"trial","name":"(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors","route":"/trials/nct05208047/","field":"status","current":"recruiting","proposed":"active","reason":"Primary completion date 2025-09-30 has passed (actual) and the registry status is RECRUITING","source":"https://clinicaltrials.gov/study/NCT05208047","registryValue":"RECRUITING; primary completion 2025-09-30","proposedOn":"2026-10-26"},{"id":"nct04711252","kind":"trial","name":"A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease","route":"/trials/nct04711252/","field":"enrolled","current":"1370","proposed":"1371","reason":"ClinicalTrials.gov actual enrolment is 1371","source":"https://clinicaltrials.gov/study/NCT04711252","registryValue":"1371 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"nct06188520","kind":"trial","name":"A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With ","route":"/trials/nct06188520/","field":"status","current":"recruiting","proposed":"active","reason":"ClinicalTrials.gov overall status is ACTIVE_NOT_RECRUITING","source":"https://clinicaltrials.gov/study/NCT06188520","registryValue":"ACTIVE_NOT_RECRUITING","proposedOn":"2026-10-26"},{"id":"nct06188520","kind":"trial","name":"A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With ","route":"/trials/nct06188520/","field":"enrolled","current":"564","proposed":"55","reason":"ClinicalTrials.gov actual enrolment is 55","source":"https://clinicaltrials.gov/study/NCT06188520","registryValue":"55 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"nct01804686","kind":"trial","name":"A Long-term Extension Study of PCI-32765 (Ibrutinib)","route":"/trials/nct01804686/","field":"enrolled","current":"700","proposed":"539","reason":"ClinicalTrials.gov actual enrolment is 539","source":"https://clinicaltrials.gov/study/NCT01804686","registryValue":"539 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"nct06055439","kind":"trial","name":"A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy","route":"/trials/nct06055439/","field":"status","current":"recruiting","proposed":"active","reason":"ClinicalTrials.gov overall status is ACTIVE_NOT_RECRUITING","source":"https://clinicaltrials.gov/study/NCT06055439","registryValue":"ACTIVE_NOT_RECRUITING","proposedOn":"2026-10-26"},{"id":"nct06939283","kind":"trial","name":"A Phase 1b/2 Multisite Dose-finding and Expansion Study of WTX-330 in Adult Patients With Selected Advanced or Metastatic Solid Tumors or Lymphoma","route":"/trials/nct06939283/","field":"enrolled","current":"100","proposed":"24","reason":"ClinicalTrials.gov actual enrolment is 24","source":"https://clinicaltrials.gov/study/NCT06939283","registryValue":"24 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"nct06568692","kind":"trial","name":"A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer","route":"/trials/nct06568692/","field":"enrolled","current":"90","proposed":"20","reason":"ClinicalTrials.gov actual enrolment is 20","source":"https://clinicaltrials.gov/study/NCT06568692","registryValue":"20 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"nct06929624","kind":"trial","name":"A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx in Diffuse Large B-cell Lymphoma","route":"/trials/nct06929624/","field":"enrolled","current":"280","proposed":"282","reason":"ClinicalTrials.gov actual enrolment is 282","source":"https://clinicaltrials.gov/study/NCT06929624","registryValue":"282 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"nct06295432","kind":"trial","name":"A Phase II Clinical Trial of DZD9008 in Combination With AZD4205 in Standard Treatment Failed NSCLC Patients With EGFR Mutations (WU-KONG21)","route":"/trials/nct06295432/","field":"status","current":"recruiting","proposed":"completed","reason":"ClinicalTrials.gov overall status is COMPLETED","source":"https://clinicaltrials.gov/study/NCT06295432","registryValue":"COMPLETED","proposedOn":"2026-10-26"},{"id":"nct06295432","kind":"trial","name":"A Phase II Clinical Trial of DZD9008 in Combination With AZD4205 in Standard Treatment Failed NSCLC Patients With EGFR Mutations (WU-KONG21)","route":"/trials/nct06295432/","field":"enrolled","current":"90","proposed":"30","reason":"ClinicalTrials.gov actual enrolment is 30","source":"https://clinicaltrials.gov/study/NCT06295432","registryValue":"30 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"nct06906471","kind":"trial","name":"A Single-Arm, Blinded, Fluorescent PSMA Histopathology Trial of AS1986NS","route":"/trials/nct06906471/","field":"enrolled","current":"10","proposed":"15","reason":"ClinicalTrials.gov actual enrolment is 15","source":"https://clinicaltrials.gov/study/NCT06906471","registryValue":"15 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"nct06614192","kind":"trial","name":"A Study Assessing Adverse Events and Disease Activity of Intravenously (IV) Infused Telisotuzumab Adizutecan in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer","route":"/trials/nct06614192/","field":"phase","current":"3","proposed":"2","reason":"ClinicalTrials.gov lists phases PHASE2","source":"https://clinicaltrials.gov/study/NCT06614192","registryValue":"PHASE2","proposedOn":"2026-10-26"},{"id":"nct06857175","kind":"trial","name":"A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Urothelial Carcinoma(PANKU-Bladder01)","route":"/trials/nct06857175/","field":"status","current":"recruiting","proposed":"active","reason":"ClinicalTrials.gov overall status is ACTIVE_NOT_RECRUITING","source":"https://clinicaltrials.gov/study/NCT06857175","registryValue":"ACTIVE_NOT_RECRUITING","proposedOn":"2026-10-26"},{"id":"nct06857175","kind":"trial","name":"A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Urothelial Carcinoma(PANKU-Bladder01)","route":"/trials/nct06857175/","field":"enrolled","current":"508","proposed":"515","reason":"ClinicalTrials.gov actual enrolment is 515","source":"https://clinicaltrials.gov/study/NCT06857175","registryValue":"515 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"nct06498986","kind":"trial","name":"A Study of BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer","route":"/trials/nct06498986/","field":"enrolled","current":"40","proposed":"76","reason":"ClinicalTrials.gov actual enrolment is 76","source":"https://clinicaltrials.gov/study/NCT06498986","registryValue":"76 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"nct05667506","kind":"trial","name":"A Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric)","route":"/trials/nct05667506/","field":"status","current":"recruiting","proposed":"active","reason":"Primary completion date 2025-05-30 has passed (actual) and the registry status is RECRUITING","source":"https://clinicaltrials.gov/study/NCT05667506","registryValue":"RECRUITING; primary completion 2025-05-30","proposedOn":"2026-10-26"},{"id":"nct06623136","kind":"trial","name":"A Study of ES102 in Combination With Toripalimab in Subjects With Advanced Non-small Cell Lung Cancer","route":"/trials/nct06623136/","field":"status","current":"recruiting","proposed":"active","reason":"ClinicalTrials.gov overall status is ACTIVE_NOT_RECRUITING","source":"https://clinicaltrials.gov/study/NCT06623136","registryValue":"ACTIVE_NOT_RECRUITING","proposedOn":"2026-10-26"},{"id":"nct06623136","kind":"trial","name":"A Study of ES102 in Combination With Toripalimab in Subjects With Advanced Non-small Cell Lung Cancer","route":"/trials/nct06623136/","field":"enrolled","current":"40","proposed":"30","reason":"ClinicalTrials.gov actual enrolment is 30","source":"https://clinicaltrials.gov/study/NCT06623136","registryValue":"30 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"nct06703398","kind":"trial","name":"A Study of GC101 TIL in Advanced Melanoma","route":"/trials/nct06703398/","field":"status","current":"recruiting","proposed":"active","reason":"Primary completion date 2026-05-12 has passed (actual) and the registry status is RECRUITING","source":"https://clinicaltrials.gov/study/NCT06703398","registryValue":"RECRUITING; primary completion 2026-05-12","proposedOn":"2026-10-26"},{"id":"nct05957367","kind":"trial","name":"A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies","route":"/trials/nct05957367/","field":"status","current":"recruiting","proposed":"active","reason":"ClinicalTrials.gov overall status is ACTIVE_NOT_RECRUITING","source":"https://clinicaltrials.gov/study/NCT05957367","registryValue":"ACTIVE_NOT_RECRUITING","proposedOn":"2026-10-26"},{"id":"nct07266441","kind":"trial","name":"A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma","route":"/trials/nct07266441/","field":"enrolled","current":"157","proposed":"168","reason":"ClinicalTrials.gov actual enrolment is 168","source":"https://clinicaltrials.gov/study/NCT07266441","registryValue":"168 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"nct06792695","kind":"trial","name":"A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer","route":"/trials/nct06792695/","field":"status","current":"recruiting","proposed":"active","reason":"ClinicalTrials.gov overall status is ACTIVE_NOT_RECRUITING","source":"https://clinicaltrials.gov/study/NCT06792695","registryValue":"ACTIVE_NOT_RECRUITING","proposedOn":"2026-10-26"},{"id":"nct06792695","kind":"trial","name":"A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer","route":"/trials/nct06792695/","field":"enrolled","current":"80","proposed":"82","reason":"ClinicalTrials.gov actual enrolment is 82","source":"https://clinicaltrials.gov/study/NCT06792695","registryValue":"82 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"nct05023980","kind":"trial","name":"A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)","route":"/trials/nct05023980/","field":"enrolled","current":"309","proposed":"282","reason":"ClinicalTrials.gov actual enrolment is 282","source":"https://clinicaltrials.gov/study/NCT05023980","registryValue":"282 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"nct07183189","kind":"trial","name":"A Study of SHR-A2009 Combined With Aumolertinib Versus Aumolertinib for First-line Treatment in EGFR-mutated, Advanced or Metastatic NSCLC","route":"/trials/nct07183189/","field":"enrolled","current":"576","proposed":"582","reason":"ClinicalTrials.gov actual enrolment is 582","source":"https://clinicaltrials.gov/study/NCT07183189","registryValue":"582 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"nct06279364","kind":"trial","name":"A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer","route":"/trials/nct06279364/","field":"status","current":"recruiting","proposed":"active","reason":"ClinicalTrials.gov overall status is ACTIVE_NOT_RECRUITING","source":"https://clinicaltrials.gov/study/NCT06279364","registryValue":"ACTIVE_NOT_RECRUITING","proposedOn":"2026-10-26"},{"id":"nct06279364","kind":"trial","name":"A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer","route":"/trials/nct06279364/","field":"enrolled","current":"524","proposed":"537","reason":"ClinicalTrials.gov actual enrolment is 537","source":"https://clinicaltrials.gov/study/NCT06279364","registryValue":"537 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"nct07428044","kind":"trial","name":"A Study of Trastuzumab Deruxtecan in People With Non-Small Cell Lung Cancer","route":"/trials/nct07428044/","field":"status","current":"recruiting","proposed":"withdrawn","reason":"ClinicalTrials.gov overall status is WITHDRAWN (sponsor closed study)","source":"https://clinicaltrials.gov/study/NCT07428044","registryValue":"WITHDRAWN","proposedOn":"2026-10-26"},{"id":"nct06833008","kind":"trial","name":"A Study to Assess a New Medicine Called IPN01195 When Administered Alone in Adults With Advanced Solid Tumours","route":"/trials/nct06833008/","field":"enrolled","current":"85","proposed":"42","reason":"ClinicalTrials.gov actual enrolment is 42","source":"https://clinicaltrials.gov/study/NCT06833008","registryValue":"42 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"nct06109272","kind":"trial","name":"A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)","route":"/trials/nct06109272/","field":"enrolled","current":"660","proposed":"89","reason":"ClinicalTrials.gov actual enrolment is 89","source":"https://clinicaltrials.gov/study/NCT06109272","registryValue":"89 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"nct06952478","kind":"trial","name":"A Study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination With Lenalidomide and Dexamethasone","route":"/trials/nct06952478/","field":"status","current":"recruiting","proposed":"active","reason":"ClinicalTrials.gov overall status is ACTIVE_NOT_RECRUITING","source":"https://clinicaltrials.gov/study/NCT06952478","registryValue":"ACTIVE_NOT_RECRUITING","proposedOn":"2026-10-26"},{"id":"nct06952478","kind":"trial","name":"A Study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination With Lenalidomide and Dexamethasone","route":"/trials/nct06952478/","field":"enrolled","current":"486","proposed":"473","reason":"ClinicalTrials.gov actual enrolment is 473","source":"https://clinicaltrials.gov/study/NCT06952478","registryValue":"473 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"nct06356311","kind":"trial","name":"A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)","route":"/trials/nct06356311/","field":"enrolled","current":"450","proposed":"473","reason":"ClinicalTrials.gov actual enrolment is 473","source":"https://clinicaltrials.gov/study/NCT06356311","registryValue":"473 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"nct06399757","kind":"trial","name":"A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors","route":"/trials/nct06399757/","field":"phase","current":"1/2","proposed":"1","reason":"ClinicalTrials.gov lists phases PHASE1","source":"https://clinicaltrials.gov/study/NCT06399757","registryValue":"PHASE1","proposedOn":"2026-10-26"},{"id":"nct06399757","kind":"trial","name":"A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors","route":"/trials/nct06399757/","field":"enrolled","current":"100","proposed":"27","reason":"ClinicalTrials.gov actual enrolment is 27","source":"https://clinicaltrials.gov/study/NCT06399757","registryValue":"27 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"nct06417814","kind":"trial","name":"A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participan","route":"/trials/nct06417814/","field":"enrolled","current":"744","proposed":"768","reason":"ClinicalTrials.gov actual enrolment is 768","source":"https://clinicaltrials.gov/study/NCT06417814","registryValue":"768 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"nct05020236","kind":"trial","name":"A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments","route":"/trials/nct05020236/","field":"status","current":"recruiting","proposed":"active","reason":"Primary completion date 2026-02-26 has passed (actual) and the registry status is RECRUITING","source":"https://clinicaltrials.gov/study/NCT05020236","registryValue":"RECRUITING; primary completion 2026-02-26","proposedOn":"2026-10-26"},{"id":"abc-02","kind":"trial","name":"ABC-02","route":"/trials/abc-02/","field":"enrolled","current":"410","proposed":"324","reason":"ClinicalTrials.gov actual enrolment is 324","source":"https://clinicaltrials.gov/study/NCT00262769","registryValue":"324 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"nct03897543","kind":"trial","name":"ABX196 in Combination With Nivolumab in Patients With Hepatocellular Carcinoma","route":"/trials/nct03897543/","field":"enrolled","current":"48","proposed":"10","reason":"ClinicalTrials.gov actual enrolment is 10","source":"https://clinicaltrials.gov/study/NCT03897543","registryValue":"10 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"acosog-z0011","kind":"trial","name":"ACOSOG Z0011 (Alliance)","route":"/trials/acosog-z0011/","field":"enrolled","current":"891","proposed":"605","reason":"ClinicalTrials.gov actual enrolment is 605","source":"https://clinicaltrials.gov/study/NCT00003855","registryValue":"605 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"admec-o","kind":"trial","name":"ADMEC-O (adjuvant nivolumab in completely resected Merkel cell carcinoma)","route":"/trials/admec-o/","field":"enrolled","current":"179","proposed":"180","reason":"ClinicalTrials.gov actual enrolment is 180","source":"https://clinicaltrials.gov/study/NCT02196961","registryValue":"180 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"nct05601752","kind":"trial","name":"ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Ovarian Cancer (SURPASS-3)","route":"/trials/nct05601752/","field":"enrolled","current":"66","proposed":"21","reason":"ClinicalTrials.gov actual enrolment is 21","source":"https://clinicaltrials.gov/study/NCT05601752","registryValue":"21 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"affinity-custirsen","kind":"trial","name":"AFFINITY","route":"/trials/affinity-custirsen/","field":"enrolled","current":"635","proposed":"630","reason":"ClinicalTrials.gov actual enrolment is 630","source":"https://clinicaltrials.gov/study/NCT01578655","registryValue":"630 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"calgb-50303","kind":"trial","name":"Alliance/CALGB 50303","route":"/trials/calgb-50303/","field":"enrolled","current":"491","proposed":"524","reason":"ClinicalTrials.gov actual enrolment is 524","source":"https://clinicaltrials.gov/study/NCT00118209","registryValue":"524 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"amaros","kind":"trial","name":"AMAROS (EORTC 10981-22023)","route":"/trials/amaros/","field":"enrolled","current":"1425","proposed":"4813","reason":"ClinicalTrials.gov actual enrolment is 4813","source":"https://clinicaltrials.gov/study/NCT00014612","registryValue":"4813 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"amplify","kind":"trial","name":"AMPLIFY","route":"/trials/amplify/","field":"enrolled","current":"867","proposed":"984","reason":"ClinicalTrials.gov actual enrolment is 984","source":"https://clinicaltrials.gov/study/NCT03836261","registryValue":"984 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"aphinity","kind":"trial","name":"APHINITY","route":"/trials/aphinity/","field":"enrolled","current":"4805","proposed":"4804","reason":"ClinicalTrials.gov actual enrolment is 4804","source":"https://clinicaltrials.gov/study/NCT01358877","registryValue":"4804 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"armor3-sv","kind":"trial","name":"ARMOR3-SV","route":"/trials/armor3-sv/","field":"enrolled","current":"38","proposed":"953","reason":"ClinicalTrials.gov actual enrolment is 953","source":"https://clinicaltrials.gov/study/NCT02438007","registryValue":"953 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"nct06498479","kind":"trial","name":"ARTEMIS-008：HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer","route":"/trials/nct06498479/","field":"enrolled","current":"460","proposed":"461","reason":"ClinicalTrials.gov actual enrolment is 461","source":"https://clinicaltrials.gov/study/NCT06498479","registryValue":"461 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"ascent-03","kind":"trial","name":"ASCENT-03","route":"/trials/ascent-03/","field":"enrolled","current":"558","proposed":"623","reason":"ClinicalTrials.gov actual enrolment is 623","source":"https://clinicaltrials.gov/study/NCT05382299","registryValue":"623 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"astra","kind":"trial","name":"ASTRA","route":"/trials/astra/","field":"enrolled","current":"401","proposed":"233","reason":"ClinicalTrials.gov actual enrolment is 233","source":"https://clinicaltrials.gov/study/NCT01843062","registryValue":"233 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"aura3","kind":"trial","name":"AURA3","route":"/trials/aura3/","field":"enrolled","current":"419","proposed":"421","reason":"ClinicalTrials.gov actual enrolment is 421","source":"https://clinicaltrials.gov/study/NCT02151981","registryValue":"421 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"nct00722228","kind":"trial","name":"Autologous and Allogeneic Whole Cell Cancer Vaccine for Metastatic Tumors","route":"/trials/nct00722228/","field":"status","current":"recruiting","proposed":"active","reason":"Primary completion date 2025-03 has passed (actual) and the registry status is RECRUITING","source":"https://clinicaltrials.gov/study/NCT00722228","registryValue":"RECRUITING; primary completion 2025-03","proposedOn":"2026-10-26"},{"id":"beacon-crc","kind":"trial","name":"BEACON CRC","route":"/trials/beacon-crc/","field":"enrolled","current":"665","proposed":"702","reason":"ClinicalTrials.gov actual enrolment is 702","source":"https://clinicaltrials.gov/study/NCT02928224","registryValue":"702 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"blue-c","kind":"trial","name":"BLUE-C","route":"/trials/blue-c/","field":"enrolled","current":"20176","proposed":"26758","reason":"ClinicalTrials.gov actual enrolment is 26758","source":"https://clinicaltrials.gov/study/NCT04144738","registryValue":"26758 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"nct04404283","kind":"trial","name":"Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL","route":"/trials/nct04404283/","field":"enrolled","current":"239","proposed":"240","reason":"ClinicalTrials.gov actual enrolment is 240","source":"https://clinicaltrials.gov/study/NCT04404283","registryValue":"240 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"bwel","kind":"trial","name":"BWEL (Breast Cancer Weight Loss, Alliance A011401)","route":"/trials/bwel/","field":"enrolled","current":"3181","proposed":"3177","reason":"ClinicalTrials.gov actual enrolment is 3177","source":"https://clinicaltrials.gov/study/NCT02750826","registryValue":"3177 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"c-144-01","kind":"trial","name":"C-144-01","route":"/trials/c-144-01/","field":"enrolled","current":"153","proposed":"220","reason":"ClinicalTrials.gov actual enrolment is 220","source":"https://clinicaltrials.gov/study/NCT02360579","registryValue":"220 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"ca184-043-ipilimumab","kind":"trial","name":"CA184-043","route":"/trials/ca184-043-ipilimumab/","field":"enrolled","current":"799","proposed":"988","reason":"ClinicalTrials.gov actual enrolment is 988","source":"https://clinicaltrials.gov/study/NCT00861614","registryValue":"988 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"capitello-291","kind":"trial","name":"CAPItello-291","route":"/trials/capitello-291/","field":"enrolled","current":"708","proposed":"818","reason":"ClinicalTrials.gov actual enrolment is 818","source":"https://clinicaltrials.gov/study/NCT04305496","registryValue":"818 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"card","kind":"trial","name":"CARD","route":"/trials/card/","field":"phase","current":"3","proposed":"4","reason":"ClinicalTrials.gov lists phases PHASE4","source":"https://clinicaltrials.gov/study/NCT02485691","registryValue":"PHASE4","proposedOn":"2026-10-26"},{"id":"cartitude-1","kind":"trial","name":"CARTITUDE-1","route":"/trials/cartitude-1/","field":"enrolled","current":"97","proposed":"126","reason":"ClinicalTrials.gov actual enrolment is 126","source":"https://clinicaltrials.gov/study/NCT03548207","registryValue":"126 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"caspian","kind":"trial","name":"CASPIAN","route":"/trials/caspian/","field":"enrolled","current":"805","proposed":"987","reason":"ClinicalTrials.gov actual enrolment is 987","source":"https://clinicaltrials.gov/study/NCT03043872","registryValue":"987 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"checkmate-143","kind":"trial","name":"CheckMate 143","route":"/trials/checkmate-143/","field":"enrolled","current":"369","proposed":"529","reason":"ClinicalTrials.gov actual enrolment is 529","source":"https://clinicaltrials.gov/study/NCT02017717","registryValue":"529 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"checkmate-205","kind":"trial","name":"CheckMate 205","route":"/trials/checkmate-205/","field":"enrolled","current":"243","proposed":"294","reason":"ClinicalTrials.gov actual enrolment is 294","source":"https://clinicaltrials.gov/study/NCT02181738","registryValue":"294 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"checkmate-649","kind":"trial","name":"CheckMate 649","route":"/trials/checkmate-649/","field":"enrolled","current":"1581","proposed":"2031","reason":"ClinicalTrials.gov actual enrolment is 2031","source":"https://clinicaltrials.gov/study/NCT02872116","registryValue":"2031 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"checkmate-816","kind":"trial","name":"CheckMate 816","route":"/trials/checkmate-816/","field":"enrolled","current":"358","proposed":"505","reason":"ClinicalTrials.gov actual enrolment is 505","source":"https://clinicaltrials.gov/study/NCT02998528","registryValue":"505 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"chronos","kind":"trial","name":"CHRONOS","route":"/trials/chronos/","field":"enrolled","current":"27","proposed":"32","reason":"ClinicalTrials.gov actual enrolment is 32","source":"https://clinicaltrials.gov/study/NCT03227926","registryValue":"32 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"clarinet","kind":"trial","name":"CLARINET","route":"/trials/clarinet/","field":"enrolled","current":"204","proposed":"264","reason":"ClinicalTrials.gov actual enrolment is 264","source":"https://clinicaltrials.gov/study/NCT00353496","registryValue":"264 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"nct04684147","kind":"trial","name":"Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia","route":"/trials/nct04684147/","field":"status","current":"recruiting","proposed":"active","reason":"Primary completion date 2022-09-22 has passed (actual) and the registry status is RECRUITING","source":"https://clinicaltrials.gov/study/NCT04684147","registryValue":"RECRUITING; primary completion 2022-09-22","proposedOn":"2026-10-26"},{"id":"nct06422936","kind":"trial","name":"Clinical Trial to Evaluate BO-112 in Patients With Basal Cell Carcinoma (BCC)","route":"/trials/nct06422936/","field":"enrolled","current":"60","proposed":"50","reason":"ClinicalTrials.gov actual enrolment is 50","source":"https://clinicaltrials.gov/study/NCT06422936","registryValue":"50 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"codebreak-100","kind":"trial","name":"CodeBreaK 100 (pancreatic cancer cohort)","route":"/trials/codebreak-100/","field":"enrolled","current":"38","proposed":"713","reason":"ClinicalTrials.gov actual enrolment is 713","source":"https://clinicaltrials.gov/study/NCT03600883","registryValue":"713 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"anbl0032","kind":"trial","name":"COG ANBL0032","route":"/trials/anbl0032/","field":"enrolled","current":"226","proposed":"1449","reason":"ClinicalTrials.gov actual enrolment is 1449","source":"https://clinicaltrials.gov/study/NCT00026312","registryValue":"1449 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"columbus","kind":"trial","name":"COLUMBUS","route":"/trials/columbus/","field":"enrolled","current":"577","proposed":"921","reason":"ClinicalTrials.gov actual enrolment is 921","source":"https://clinicaltrials.gov/study/NCT01909453","registryValue":"921 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"crossfire","kind":"trial","name":"CROSSFIRE","route":"/trials/crossfire/","field":"enrolled","current":"68","proposed":"74","reason":"ClinicalTrials.gov actual enrolment is 74","source":"https://clinicaltrials.gov/study/NCT02791503","registryValue":"74 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"crystal-fire3","kind":"trial","name":"CRYSTAL & FIRE-3","route":"/trials/crystal-fire3/","field":"enrolled","current":"1198","proposed":"1221","reason":"ClinicalTrials.gov actual enrolment is 1221","source":"https://clinicaltrials.gov/study/NCT00154102","registryValue":"1221 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"dart-01-05-gicor","kind":"trial","name":"DART 01/05 GICOR","route":"/trials/dart-01-05-gicor/","field":"enrolled","current":"355","proposed":"362","reason":"ClinicalTrials.gov actual enrolment is 362","source":"https://clinicaltrials.gov/study/NCT02175212","registryValue":"362 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"deep-c","kind":"trial","name":"DeeP-C","route":"/trials/deep-c/","field":"enrolled","current":"9989","proposed":"12776","reason":"ClinicalTrials.gov actual enrolment is 12776","source":"https://clinicaltrials.gov/study/NCT01397747","registryValue":"12776 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"nct06778382","kind":"trial","name":"Delayed Systemic Therapy Following Destructive Local Treatment of Pulmonary Oligometastases After No Evidence of Disease (NED) in Colorectal Cancer.","route":"/trials/nct06778382/","field":"status","current":"recruiting","proposed":"active","reason":"Primary completion date 2025-11-01 has passed (actual) and the registry status is RECRUITING","source":"https://clinicaltrials.gov/study/NCT06778382","registryValue":"RECRUITING; primary completion 2025-11-01","proposedOn":"2026-10-26"},{"id":"destiny-pantumor02","kind":"trial","name":"DESTINY-PanTumor02","route":"/trials/destiny-pantumor02/","field":"enrolled","current":"267","proposed":"477","reason":"ClinicalTrials.gov actual enrolment is 477","source":"https://clinicaltrials.gov/study/NCT04482309","registryValue":"477 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"nct05640791","kind":"trial","name":"Durvalumab Combined With Chemotherapy Neoadjuvant Therapy of Biliary Tract Cancer","route":"/trials/nct05640791/","field":"status","current":"recruiting","proposed":"active","reason":"Primary completion date 2023-12-31 has passed (actual) and the registry status is RECRUITING","source":"https://clinicaltrials.gov/study/NCT05640791","registryValue":"RECRUITING; primary completion 2023-12-31","proposedOn":"2026-10-26"},{"id":"nct04844866","kind":"trial","name":"Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients","route":"/trials/nct04844866/","field":"status","current":"recruiting","proposed":"active","reason":"Primary completion date 2025-01-15 has passed (actual) and the registry status is RECRUITING","source":"https://clinicaltrials.gov/study/NCT04844866","registryValue":"RECRUITING; primary completion 2025-01-15","proposedOn":"2026-10-26"},{"id":"nct06050122","kind":"trial","name":"Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin Syndrome","route":"/trials/nct06050122/","field":"enrolled","current":"140","proposed":"113","reason":"ClinicalTrials.gov actual enrolment is 113","source":"https://clinicaltrials.gov/study/NCT06050122","registryValue":"113 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"elara","kind":"trial","name":"ELARA","route":"/trials/elara/","field":"enrolled","current":"97","proposed":"98","reason":"ClinicalTrials.gov actual enrolment is 98","source":"https://clinicaltrials.gov/study/NCT03568461","registryValue":"98 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"eliana","kind":"trial","name":"ELIANA","route":"/trials/eliana/","field":"enrolled","current":"79","proposed":"80","reason":"ClinicalTrials.gov actual enrolment is 80","source":"https://clinicaltrials.gov/study/NCT02435849","registryValue":"80 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"emerald-1","kind":"trial","name":"EMERALD-1","route":"/trials/emerald-1/","field":"enrolled","current":"616","proposed":"724","reason":"ClinicalTrials.gov actual enrolment is 724","source":"https://clinicaltrials.gov/study/NCT03778957","registryValue":"724 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"enthuse-m1-zibotentan","kind":"trial","name":"ENTHUSE M1","route":"/trials/enthuse-m1-zibotentan/","field":"enrolled","current":"594","proposed":"896","reason":"ClinicalTrials.gov actual enrolment is 896","source":"https://clinicaltrials.gov/study/NCT00554229","registryValue":"896 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"eortc-22033","kind":"trial","name":"EORTC 22033-26033","route":"/trials/eortc-22033/","field":"enrolled","current":"477","proposed":"709","reason":"ClinicalTrials.gov actual enrolment is 709","source":"https://clinicaltrials.gov/study/NCT00182819","registryValue":"709 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"eortc-h10","kind":"trial","name":"EORTC/LYSA/FIL H10","route":"/trials/eortc-h10/","field":"enrolled","current":"1925","proposed":"1952","reason":"ClinicalTrials.gov actual enrolment is 1952","source":"https://clinicaltrials.gov/study/NCT00433433","registryValue":"1952 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"epcore-dlbcl-1","kind":"trial","name":"EPCORE DLBCL-1","route":"/trials/epcore-dlbcl-1/","field":"enrolled","current":"552","proposed":"483","reason":"ClinicalTrials.gov actual enrolment is 483","source":"https://clinicaltrials.gov/study/NCT04628494","registryValue":"483 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"epcore-nhl-1","kind":"trial","name":"EPCORE NHL-1","route":"/trials/epcore-nhl-1/","field":"enrolled","current":"157","proposed":"666","reason":"ClinicalTrials.gov actual enrolment is 666","source":"https://clinicaltrials.gov/study/NCT03625037","registryValue":"666 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"esphall","kind":"trial","name":"EsPhALL (EsPhALL2004 and EsPhALL2010)","route":"/trials/esphall/","field":"enrolled","current":"178","proposed":"49","reason":"ClinicalTrials.gov actual enrolment is 49","source":"https://clinicaltrials.gov/study/NCT00287105","registryValue":"49 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"euramos-1","kind":"trial","name":"EURAMOS-1","route":"/trials/euramos-1/","field":"enrolled","current":"2260","proposed":"1334","reason":"ClinicalTrials.gov actual enrolment is 1334","source":"https://clinicaltrials.gov/study/NCT00134030","registryValue":"1334 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"ev-303","kind":"trial","name":"EV-303 / KEYNOTE-905","route":"/trials/ev-303/","field":"enrolled","current":"344","proposed":"595","reason":"ClinicalTrials.gov actual enrolment is 595","source":"https://clinicaltrials.gov/study/NCT03924895","registryValue":"595 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"nct05482516","kind":"trial","name":"Evaluating Novel Therapies in ctDNA Positive GI Cancers","route":"/trials/nct05482516/","field":"enrolled","current":"20","proposed":"11","reason":"ClinicalTrials.gov actual enrolment is 11","source":"https://clinicaltrials.gov/study/NCT05482516","registryValue":"11 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"evera","kind":"trial","name":"evERA","route":"/trials/evera/","field":"enrolled","current":"320","proposed":"373","reason":"ClinicalTrials.gov actual enrolment is 373","source":"https://clinicaltrials.gov/study/NCT05306340","registryValue":"373 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"nct05647122","kind":"trial","name":"First in Human Study of AZD9592 in Solid Tumors","route":"/trials/nct05647122/","field":"enrolled","current":"167","proposed":"190","reason":"ClinicalTrials.gov actual enrolment is 190","source":"https://clinicaltrials.gov/study/NCT05647122","registryValue":"190 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"flaura","kind":"trial","name":"FLAURA","route":"/trials/flaura/","field":"enrolled","current":"556","proposed":"674","reason":"ClinicalTrials.gov actual enrolment is 674","source":"https://clinicaltrials.gov/study/NCT02296125","registryValue":"674 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"fort","kind":"trial","name":"FoRT","route":"/trials/fort/","field":"enrolled","current":"548","proposed":"614","reason":"ClinicalTrials.gov actual enrolment is 614","source":"https://clinicaltrials.gov/study/NCT00310167","registryValue":"614 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"nct06484153","kind":"trial","name":"Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Advanced or Metastatic pMMR/MSS Colorectal Carcinoma","route":"/trials/nct06484153/","field":"status","current":"recruiting","proposed":"active","reason":"Primary completion date 2026-07-22 has passed (actual) and the registry status is RECRUITING","source":"https://clinicaltrials.gov/study/NCT06484153","registryValue":"RECRUITING; primary completion 2026-07-22","proposedOn":"2026-10-26"},{"id":"hd18","kind":"trial","name":"GHSG HD18","route":"/trials/hd18/","field":"enrolled","current":"1945","proposed":"1500","reason":"ClinicalTrials.gov actual enrolment is 1500","source":"https://clinicaltrials.gov/study/NCT00515554","registryValue":"1500 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"nct05451602","kind":"trial","name":"HEC169096 in Participants With Advanced Solid Tumors","route":"/trials/nct05451602/","field":"enrolled","current":"456","proposed":"24","reason":"ClinicalTrials.gov actual enrolment is 24","source":"https://clinicaltrials.gov/study/NCT05451602","registryValue":"24 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"nct03364530","kind":"trial","name":"Hepatic Arterial Infusion of Gemcitabine-oxaliplatin for Second-line Therapy in Non-metastatic Unresectable Intra-hepatic Cholangiocarcinoma","route":"/trials/nct03364530/","field":"status","current":"recruiting","proposed":"active","reason":"Primary completion date 2025-10-21 has passed (actual) and the registry status is RECRUITING","source":"https://clinicaltrials.gov/study/NCT03364530","registryValue":"RECRUITING; primary completion 2025-10-21","proposedOn":"2026-10-26"},{"id":"hero","kind":"trial","name":"HERO","route":"/trials/hero/","field":"enrolled","current":"930","proposed":"1134","reason":"ClinicalTrials.gov actual enrolment is 1134","source":"https://clinicaltrials.gov/study/NCT03085095","registryValue":"1134 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"himalaya","kind":"trial","name":"HIMALAYA","route":"/trials/himalaya/","field":"enrolled","current":"1171","proposed":"1324","reason":"ClinicalTrials.gov actual enrolment is 1324","source":"https://clinicaltrials.gov/study/NCT03298451","registryValue":"1324 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"nct06435260","kind":"trial","name":"Hypofractionated Radiotherapy +Chemotherapy+ Camrelizumab as Neoadjuvant Therapy for Pancreatic Cancer","route":"/trials/nct06435260/","field":"status","current":"recruiting","proposed":"active","reason":"Primary completion date 2025-06-01 has passed (actual) and the registry status is RECRUITING","source":"https://clinicaltrials.gov/study/NCT06435260","registryValue":"RECRUITING; primary completion 2025-06-01","proposedOn":"2026-10-26"},{"id":"ignyte-eso","kind":"trial","name":"IGNYTE-ESO","route":"/trials/ignyte-eso/","field":"enrolled","current":"64","proposed":"103","reason":"ClinicalTrials.gov actual enrolment is 103","source":"https://clinicaltrials.gov/study/NCT03967223","registryValue":"103 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"imbrave150","kind":"trial","name":"IMbrave150","route":"/trials/imbrave150/","field":"enrolled","current":"501","proposed":"558","reason":"ClinicalTrials.gov actual enrolment is 558","source":"https://clinicaltrials.gov/study/NCT03434379","registryValue":"558 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"imforte","kind":"trial","name":"IMforte","route":"/trials/imforte/","field":"enrolled","current":"483","proposed":"660","reason":"ClinicalTrials.gov actual enrolment is 660","source":"https://clinicaltrials.gov/study/NCT05091567","registryValue":"660 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"immagine-1","kind":"trial","name":"iMMagine-1","route":"/trials/immagine-1/","field":"enrolled","current":"117","proposed":"136","reason":"ClinicalTrials.gov actual enrolment is 136","source":"https://clinicaltrials.gov/study/NCT05396885","registryValue":"136 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"nct05027776","kind":"trial","name":"Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years","route":"/trials/nct05027776/","field":"status","current":"recruiting","proposed":"active","reason":"Primary completion date 2023-11-22 has passed (actual) and the registry status is UNKNOWN","source":"https://clinicaltrials.gov/study/NCT05027776","registryValue":"UNKNOWN; primary completion 2023-11-22","proposedOn":"2026-10-26"},{"id":"impower133","kind":"trial","name":"IMpower133","route":"/trials/impower133/","field":"enrolled","current":"403","proposed":"503","reason":"ClinicalTrials.gov actual enrolment is 503","source":"https://clinicaltrials.gov/study/NCT02763579","registryValue":"503 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"insema","kind":"trial","name":"INSEMA (Intergroup Sentinel Mamma)","route":"/trials/insema/","field":"enrolled","current":"5502","proposed":"5505","reason":"ClinicalTrials.gov actual enrolment is 5505","source":"https://clinicaltrials.gov/study/NCT02466737","registryValue":"5505 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"ipatunity130","kind":"trial","name":"IPATunity130","route":"/trials/ipatunity130/","field":"enrolled","current":"255","proposed":"579","reason":"ClinicalTrials.gov actual enrolment is 579","source":"https://clinicaltrials.gov/study/NCT03337724","registryValue":"579 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"isg-sts-1001","kind":"trial","name":"ISG-STS 1001","route":"/trials/isg-sts-1001/","field":"enrolled","current":"287","proposed":"550","reason":"ClinicalTrials.gov actual enrolment is 550","source":"https://clinicaltrials.gov/study/NCT01710176","registryValue":"550 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"istopmm","kind":"trial","name":"iStopMM","route":"/trials/istopmm/","field":"enrolled","current":"75422","proposed":"80761","reason":"ClinicalTrials.gov actual enrolment is 80761","source":"https://clinicaltrials.gov/study/NCT03327597","registryValue":"80761 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"keynote-170","kind":"trial","name":"KEYNOTE-170","route":"/trials/keynote-170/","field":"enrolled","current":"53","proposed":"80","reason":"ClinicalTrials.gov actual enrolment is 80","source":"https://clinicaltrials.gov/study/NCT02576990","registryValue":"80 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"nct03667170","kind":"trial","name":"KN035 for dMMR/MSI-H Advanced Solid Tumors","route":"/trials/nct03667170/","field":"enrolled","current":"200","proposed":"188","reason":"ClinicalTrials.gov actual enrolment is 188","source":"https://clinicaltrials.gov/study/NCT03667170","registryValue":"188 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"lummicar-1","kind":"trial","name":"LUMMICAR STUDY 1","route":"/trials/lummicar-1/","field":"enrolled","current":"102","proposed":"121","reason":"ClinicalTrials.gov actual enrolment is 121","source":"https://clinicaltrials.gov/study/NCT03975907","registryValue":"121 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"lurbinectedin-basket-sclc","kind":"trial","name":"Lurbinectedin basket trial, small-cell lung cancer cohort","route":"/trials/lurbinectedin-basket-sclc/","field":"enrolled","current":"105","proposed":"345","reason":"ClinicalTrials.gov actual enrolment is 345","source":"https://clinicaltrials.gov/study/NCT02454972","registryValue":"345 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"lyma","kind":"trial","name":"LyMa","route":"/trials/lyma/","field":"enrolled","current":"240","proposed":"299","reason":"ClinicalTrials.gov actual enrolment is 299","source":"https://clinicaltrials.gov/study/NCT00921414","registryValue":"299 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"magnetismm-3","kind":"trial","name":"MagnetisMM-3","route":"/trials/magnetismm-3/","field":"enrolled","current":"123","proposed":"187","reason":"ClinicalTrials.gov actual enrolment is 187","source":"https://clinicaltrials.gov/study/NCT04649359","registryValue":"187 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"magnitude","kind":"trial","name":"MAGNITUDE","route":"/trials/magnitude/","field":"enrolled","current":"423","proposed":"765","reason":"ClinicalTrials.gov actual enrolment is 765","source":"https://clinicaltrials.gov/study/NCT03748641","registryValue":"765 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"majestec-1","kind":"trial","name":"MajesTEC-1","route":"/trials/majestec-1/","field":"phase","current":"1/2","proposed":"2","reason":"ClinicalTrials.gov lists phases PHASE2","source":"https://clinicaltrials.gov/study/NCT04557098","registryValue":"PHASE2","proposedOn":"2026-10-26"},{"id":"majestec-1","kind":"trial","name":"MajesTEC-1","route":"/trials/majestec-1/","field":"enrolled","current":"165","proposed":"194","reason":"ClinicalTrials.gov actual enrolment is 194","source":"https://clinicaltrials.gov/study/NCT04557098","registryValue":"194 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"nct06349590","kind":"trial","name":"Manipulation of the Gut Microbiome by a Standardized Preoperative Diet to Prevent Colorectal Cancer Recurrence and Metastasis Following Surgery","route":"/trials/nct06349590/","field":"status","current":"recruiting","proposed":"active","reason":"Primary completion date 2026-04-06 has passed (actual) and the registry status is RECRUITING","source":"https://clinicaltrials.gov/study/NCT06349590","registryValue":"RECRUITING; primary completion 2026-04-06","proposedOn":"2026-10-26"},{"id":"masai","kind":"trial","name":"MASAI (Mammography Screening with Artificial Intelligence)","route":"/trials/masai/","field":"enrolled","current":"105934","proposed":"100000","reason":"ClinicalTrials.gov actual enrolment is 100000","source":"https://clinicaltrials.gov/study/NCT04838756","registryValue":"100000 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"nct04084496","kind":"trial","name":"mFOLFIRINOX as Adjuvent Chemotherapy in Treating Chinese Pancreatic Cancer Patients","route":"/trials/nct04084496/","field":"status","current":"recruiting","proposed":"active","reason":"Primary completion date 2024-12-31 has passed (actual) and the registry status is RECRUITING","source":"https://clinicaltrials.gov/study/NCT04084496","registryValue":"RECRUITING; primary completion 2024-12-31","proposedOn":"2026-10-26"},{"id":"nct04110301","kind":"trial","name":"MIL62 Plus Lenalidomide for Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (FL and MZL)","route":"/trials/nct04110301/","field":"status","current":"recruiting","proposed":"active","reason":"Primary completion date 2024-01-09 has passed (actual) and the registry status is RECRUITING","source":"https://clinicaltrials.gov/study/NCT04110301","registryValue":"RECRUITING; primary completion 2024-01-09","proposedOn":"2026-10-26"},{"id":"mntx-302","kind":"trial","name":"MNTX 302","route":"/trials/mntx-302/","field":"enrolled","current":"133","proposed":"134","reason":"ClinicalTrials.gov actual enrolment is 134","source":"https://clinicaltrials.gov/study/NCT00402038","registryValue":"134 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"nct06514508","kind":"trial","name":"Mobilization of Stem Cells With Motixafortide (BL-8040) in Combination With G-CSF in Multiple Myeloma Patients","route":"/trials/nct06514508/","field":"status","current":"recruiting","proposed":"active","reason":"Primary completion date 2026-09-11 has passed (actual) and the registry status is RECRUITING","source":"https://clinicaltrials.gov/study/NCT06514508","registryValue":"RECRUITING; primary completion 2026-09-11","proposedOn":"2026-10-26"},{"id":"monumental-1","kind":"trial","name":"MonumenTAL-1","route":"/trials/monumental-1/","field":"phase","current":"1/2","proposed":"2","reason":"ClinicalTrials.gov lists phases PHASE2","source":"https://clinicaltrials.gov/study/NCT04634552","registryValue":"PHASE2","proposedOn":"2026-10-26"},{"id":"nct07472868","kind":"trial","name":"Neoadjuvant FOLFOXIRI and Chemoradiotherapy Versus Neoadjuvant CAPOX/FOLFOX and Chemoradiotherapy Followed by Surgery or a Watch-and-Wait Approach in High Risk","route":"/trials/nct07472868/","field":"status","current":"planned","proposed":"recruiting","reason":"ClinicalTrials.gov overall status is RECRUITING","source":"https://clinicaltrials.gov/study/NCT07472868","registryValue":"RECRUITING","proposedOn":"2026-10-26"},{"id":"nct07808151","kind":"trial","name":"Neoadjuvant Pembrolizumab and Porustobart in Resectable pMMR/MSS Colon Cancer","route":"/trials/nct07808151/","field":"status","current":"planned","proposed":"recruiting","reason":"ClinicalTrials.gov overall status is RECRUITING","source":"https://clinicaltrials.gov/study/NCT07808151","registryValue":"RECRUITING","proposedOn":"2026-10-26"},{"id":"nhs-galleri","kind":"trial","name":"NHS-Galleri","route":"/trials/nhs-galleri/","field":"enrolled","current":"142250","proposed":"142318","reason":"ClinicalTrials.gov actual enrolment is 142318","source":"https://clinicaltrials.gov/study/NCT05611632","registryValue":"142318 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"nct05972655","kind":"trial","name":"Nodes-sparing Short-course Radiation Combined With CAPOX and Tislelizumab for MSS Middle and Low Rectal Cancer","route":"/trials/nct05972655/","field":"status","current":"recruiting","proposed":"active","reason":"Primary completion date 2024-08-20 has passed (actual) and the registry status is RECRUITING","source":"https://clinicaltrials.gov/study/NCT05972655","registryValue":"RECRUITING; primary completion 2024-08-20","proposedOn":"2026-10-26"},{"id":"nordicc","kind":"trial","name":"NordICC (Nordic-European Initiative on Colorectal Cancer)","route":"/trials/nordicc/","field":"enrolled","current":"84585","proposed":"95000","reason":"ClinicalTrials.gov actual enrolment is 95000","source":"https://clinicaltrials.gov/study/NCT00883792","registryValue":"95000 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"norpact-1","kind":"trial","name":"NORPACT-1","route":"/trials/norpact-1/","field":"phase","current":"2","proposed":"2/3","reason":"ClinicalTrials.gov lists phases PHASE2, PHASE3","source":"https://clinicaltrials.gov/study/NCT02919787","registryValue":"PHASE2/PHASE3","proposedOn":"2026-10-26"},{"id":"olympia","kind":"trial","name":"OlympiA","route":"/trials/olympia/","field":"enrolled","current":"1836","proposed":"1837","reason":"ClinicalTrials.gov actual enrolment is 1837","source":"https://clinicaltrials.gov/study/NCT02032823","registryValue":"1837 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"nct06736717","kind":"trial","name":"Onvansertib in Combination With NALIRIFOX for First Line Treatment of Advanced Pancreatic Cancer","route":"/trials/nct06736717/","field":"enrolled","current":"21","proposed":"16","reason":"ClinicalTrials.gov actual enrolment is 16","source":"https://clinicaltrials.gov/study/NCT06736717","registryValue":"16 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"oriole","kind":"trial","name":"ORIOLE","route":"/trials/oriole/","field":"enrolled","current":"54","proposed":"80","reason":"ClinicalTrials.gov actual enrolment is 80","source":"https://clinicaltrials.gov/study/NCT02680587","registryValue":"80 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"pakt","kind":"trial","name":"PAKT","route":"/trials/pakt/","field":"enrolled","current":"140","proposed":"71","reason":"ClinicalTrials.gov actual enrolment is 71","source":"https://clinicaltrials.gov/study/NCT02423603","registryValue":"71 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"partiqol","kind":"trial","name":"PARTIQoL","route":"/trials/partiqol/","field":"enrolled","current":"450","proposed":"454","reason":"ClinicalTrials.gov actual enrolment is 454","source":"https://clinicaltrials.gov/study/NCT01617161","registryValue":"454 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"patch-transdermal-oestradiol","kind":"trial","name":"PATCH (Prostate Adenocarcinoma Transcutaneous Hormone)","route":"/trials/patch-transdermal-oestradiol/","field":"phase","current":"2/3","proposed":"3","reason":"ClinicalTrials.gov lists phases PHASE3","source":"https://clinicaltrials.gov/study/NCT00303784","registryValue":"PHASE3","proposedOn":"2026-10-26"},{"id":"pathos","kind":"trial","name":"PATHOS","route":"/trials/pathos/","field":"phase","current":"2/3","proposed":"3","reason":"ClinicalTrials.gov lists phases PHASE3","source":"https://clinicaltrials.gov/study/NCT02215265","registryValue":"PHASE3","proposedOn":"2026-10-26"},{"id":"patricia","kind":"trial","name":"PATRICIA","route":"/trials/patricia/","field":"enrolled","current":"18644","proposed":"18729","reason":"ClinicalTrials.gov actual enrolment is 18729","source":"https://clinicaltrials.gov/study/NCT00122681","registryValue":"18729 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"nct06960577","kind":"trial","name":"Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)","route":"/trials/nct06960577/","field":"phase","current":"3","proposed":"2","reason":"ClinicalTrials.gov lists phases PHASE2","source":"https://clinicaltrials.gov/study/NCT06960577","registryValue":"PHASE2","proposedOn":"2026-10-26"},{"id":"nct07162883","kind":"trial","name":"Pharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of Non-Small Cell Lung Cancer (NSCLC)","route":"/trials/nct07162883/","field":"status","current":"planned","proposed":"active","reason":"ClinicalTrials.gov overall status is ACTIVE_NOT_RECRUITING","source":"https://clinicaltrials.gov/study/NCT07162883","registryValue":"ACTIVE_NOT_RECRUITING","proposedOn":"2026-10-26"},{"id":"nct04643418","kind":"trial","name":"Phase 1/2a Study of MPB-1734 in Patients With Advanced Solid Tumors","route":"/trials/nct04643418/","field":"status","current":"recruiting","proposed":"active","reason":"Primary completion date 2025-03-31 has passed (actual) and the registry status is RECRUITING","source":"https://clinicaltrials.gov/study/NCT04643418","registryValue":"RECRUITING; primary completion 2025-03-31","proposedOn":"2026-10-26"},{"id":"nct05103358","kind":"trial","name":"Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)","route":"/trials/nct05103358/","field":"enrolled","current":"120","proposed":"128","reason":"ClinicalTrials.gov actual enrolment is 128","source":"https://clinicaltrials.gov/study/NCT05103358","registryValue":"128 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"nct04586478","kind":"trial","name":"Phase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma","route":"/trials/nct04586478/","field":"status","current":"recruiting","proposed":"active","reason":"Primary completion date 2024-03-30 has passed (actual) and the registry status is RECRUITING","source":"https://clinicaltrials.gov/study/NCT04586478","registryValue":"RECRUITING; primary completion 2024-03-30","proposedOn":"2026-10-26"},{"id":"nct05827081","kind":"trial","name":"Phase IIIb Study of Ribociclib + ET in Early Breast Cancer","route":"/trials/nct05827081/","field":"status","current":"recruiting","proposed":"active","reason":"ClinicalTrials.gov overall status is ACTIVE_NOT_RECRUITING","source":"https://clinicaltrials.gov/study/NCT05827081","registryValue":"ACTIVE_NOT_RECRUITING","proposedOn":"2026-10-26"},{"id":"nct05827081","kind":"trial","name":"Phase IIIb Study of Ribociclib + ET in Early Breast Cancer","route":"/trials/nct05827081/","field":"enrolled","current":"1400","proposed":"1464","reason":"ClinicalTrials.gov actual enrolment is 1464","source":"https://clinicaltrials.gov/study/NCT05827081","registryValue":"1464 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"nct07416058","kind":"trial","name":"PHOENIX: QL1706 Plus Chemotherapy and Bevacizumab in AGA-Resistant, PD-L1 ≥50% Non-Squamous NSCLC","route":"/trials/nct07416058/","field":"status","current":"planned","proposed":"recruiting","reason":"ClinicalTrials.gov overall status is RECRUITING","source":"https://clinicaltrials.gov/study/NCT07416058","registryValue":"RECRUITING","proposedOn":"2026-10-26"},{"id":"pod1um-201","kind":"trial","name":"POD1UM-201 (retifanlimab in advanced Merkel cell carcinoma)","route":"/trials/pod1um-201/","field":"enrolled","current":"101","proposed":"107","reason":"ClinicalTrials.gov actual enrolment is 107","source":"https://clinicaltrials.gov/study/NCT03599713","registryValue":"107 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"polargo","kind":"trial","name":"POLARGO","route":"/trials/polargo/","field":"enrolled","current":"255","proposed":"270","reason":"ClinicalTrials.gov actual enrolment is 270","source":"https://clinicaltrials.gov/study/NCT04182204","registryValue":"270 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"polarix","kind":"trial","name":"POLARIX","route":"/trials/polarix/","field":"enrolled","current":"879","proposed":"1000","reason":"ClinicalTrials.gov actual enrolment is 1000","source":"https://clinicaltrials.gov/study/NCT03274492","registryValue":"1000 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"nct04495088","kind":"trial","name":"Preoperative FOLFOX Versus Postoperative Risk-adapted Chemotherapy in Patients With Locally Advanced Rectal Cancer","route":"/trials/nct04495088/","field":"enrolled","current":"550","proposed":"215","reason":"ClinicalTrials.gov actual enrolment is 215","source":"https://clinicaltrials.gov/study/NCT04495088","registryValue":"215 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"prima-follicular","kind":"trial","name":"PRIMA","route":"/trials/prima-follicular/","field":"enrolled","current":"1018","proposed":"1217","reason":"ClinicalTrials.gov actual enrolment is 1217","source":"https://clinicaltrials.gov/study/NCT00140582","registryValue":"1217 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"nct03478488","kind":"trial","name":"Programmed Death Ligand (PD-L1) Combined With Chemotherapy for Patients With BTC","route":"/trials/nct03478488/","field":"enrolled","current":"480","proposed":"472","reason":"ClinicalTrials.gov actual enrolment is 472","source":"https://clinicaltrials.gov/study/NCT03478488","registryValue":"472 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"propel","kind":"trial","name":"PROpel","route":"/trials/propel/","field":"enrolled","current":"796","proposed":"895","reason":"ClinicalTrials.gov actual enrolment is 895","source":"https://clinicaltrials.gov/study/NCT03732820","registryValue":"895 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"protect","kind":"trial","name":"ProtecT","route":"/trials/protect/","field":"enrolled","current":"1643","proposed":"82849","reason":"ClinicalTrials.gov actual enrolment is 82849","source":"https://clinicaltrials.gov/study/NCT02044172","registryValue":"82849 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"nct07052214","kind":"trial","name":"PSMA PET Combined With MRI for the Detection of PCa","route":"/trials/nct07052214/","field":"status","current":"recruiting","proposed":"active","reason":"ClinicalTrials.gov overall status is ACTIVE_NOT_RECRUITING","source":"https://clinicaltrials.gov/study/NCT07052214","registryValue":"ACTIVE_NOT_RECRUITING","proposedOn":"2026-10-26"},{"id":"psma-prerp","kind":"trial","name":"PSMA-PreRP","route":"/trials/psma-prerp/","field":"enrolled","current":"764","proposed":"400","reason":"ClinicalTrials.gov actual enrolment is 400","source":"https://clinicaltrials.gov/study/NCT03368547","registryValue":"400 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"psmaddition","kind":"trial","name":"PSMAddition","route":"/trials/psmaddition/","field":"enrolled","current":"1144","proposed":"1140","reason":"ClinicalTrials.gov actual enrolment is 1140","source":"https://clinicaltrials.gov/study/NCT04720157","registryValue":"1140 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"ready-dasatinib","kind":"trial","name":"READY","route":"/trials/ready-dasatinib/","field":"enrolled","current":"1522","proposed":"1930","reason":"ClinicalTrials.gov actual enrolment is 1930","source":"https://clinicaltrials.gov/study/NCT00744497","registryValue":"1930 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"nct07468071","kind":"trial","name":"Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other","route":"/trials/nct07468071/","field":"enrolled","current":"40","proposed":"25","reason":"ClinicalTrials.gov actual enrolment is 25","source":"https://clinicaltrials.gov/study/NCT07468071","registryValue":"25 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"rtog-0415","kind":"trial","name":"RTOG 0415","route":"/trials/rtog-0415/","field":"enrolled","current":"1115","proposed":"1116","reason":"ClinicalTrials.gov actual enrolment is 1116","source":"https://clinicaltrials.gov/study/NCT00331773","registryValue":"1116 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"rtog-9408","kind":"trial","name":"RTOG 94-08","route":"/trials/rtog-9408/","field":"enrolled","current":"1979","proposed":"2028","reason":"ClinicalTrials.gov actual enrolment is 2028","source":"https://clinicaltrials.gov/study/NCT00002597","registryValue":"2028 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"rtog-9402","kind":"trial","name":"RTOG 9402","route":"/trials/rtog-9402/","field":"enrolled","current":"291","proposed":"299","reason":"ClinicalTrials.gov actual enrolment is 299","source":"https://clinicaltrials.gov/study/NCT00002569","registryValue":"299 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"rtog-9601","kind":"trial","name":"RTOG 9601","route":"/trials/rtog-9601/","field":"enrolled","current":"760","proposed":"840","reason":"ClinicalTrials.gov actual enrolment is 840","source":"https://clinicaltrials.gov/study/NCT00002874","registryValue":"840 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"nct06188702","kind":"trial","name":"S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP","route":"/trials/nct06188702/","field":"enrolled","current":"60","proposed":"61","reason":"ClinicalTrials.gov actual enrolment is 61","source":"https://clinicaltrials.gov/study/NCT06188702","registryValue":"61 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"sano","kind":"trial","name":"SANO","route":"/trials/sano/","field":"enrolled","current":"309","proposed":"776","reason":"ClinicalTrials.gov actual enrolment is 776","source":"https://clinicaltrials.gov/study/NCT05953181","registryValue":"776 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"screentrustcad","kind":"trial","name":"ScreenTrustCAD","route":"/trials/screentrustcad/","field":"enrolled","current":"55581","proposed":"55579","reason":"ClinicalTrials.gov actual enrolment is 55579","source":"https://clinicaltrials.gov/study/NCT04778670","registryValue":"55579 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"nct07448077","kind":"trial","name":"Short-course Radiotherapy in TNT Combined With Enlonstobart for pMMR LARC","route":"/trials/nct07448077/","field":"status","current":"recruiting","proposed":"active","reason":"Primary completion date 2026-03-01 has passed (actual) and the registry status is RECRUITING","source":"https://clinicaltrials.gov/study/NCT07448077","registryValue":"RECRUITING; primary completion 2026-03-01","proposedOn":"2026-10-26"},{"id":"nct06050317","kind":"trial","name":"Sintilimab Combined With Chemotherapy and Radiotherapy in Patients With Inoperable Pancreatic Cancer","route":"/trials/nct06050317/","field":"status","current":"recruiting","proposed":"active","reason":"Primary completion date 2025-08-18 has passed (actual) and the registry status is RECRUITING","source":"https://clinicaltrials.gov/study/NCT06050317","registryValue":"RECRUITING; primary completion 2025-08-18","proposedOn":"2026-10-26"},{"id":"solo-1","kind":"trial","name":"SOLO-1","route":"/trials/solo-1/","field":"enrolled","current":"391","proposed":"450","reason":"ClinicalTrials.gov actual enrolment is 450","source":"https://clinicaltrials.gov/study/NCT01844986","registryValue":"450 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"nct04494503","kind":"trial","name":"Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL","route":"/trials/nct04494503/","field":"status","current":"recruiting","proposed":"active","reason":"Primary completion date 2024-10-20 has passed (actual) and the registry status is RECRUITING","source":"https://clinicaltrials.gov/study/NCT04494503","registryValue":"RECRUITING; primary completion 2024-10-20","proposedOn":"2026-10-26"},{"id":"nct06297226","kind":"trial","name":"Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma","route":"/trials/nct06297226/","field":"status","current":"recruiting","proposed":"active","reason":"Primary completion date 2026-07-31 has passed (actual) and the registry status is RECRUITING","source":"https://clinicaltrials.gov/study/NCT06297226","registryValue":"RECRUITING; primary completion 2026-07-31","proposedOn":"2026-10-26"},{"id":"nct03874026","kind":"trial","name":"Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients","route":"/trials/nct03874026/","field":"status","current":"recruiting","proposed":"active","reason":"Primary completion date 2023-05-19 has passed (actual) and the registry status is RECRUITING","source":"https://clinicaltrials.gov/study/NCT03874026","registryValue":"RECRUITING; primary completion 2023-05-19","proposedOn":"2026-10-26"},{"id":"nct06935409","kind":"trial","name":"Study of HS-20093 Versus Gemcitabine in Combination With Docetaxel in Treatment of Osteosarcoma After Previous Second-line Treatment Failure","route":"/trials/nct06935409/","field":"enrolled","current":"117","proposed":"122","reason":"ClinicalTrials.gov actual enrolment is 122","source":"https://clinicaltrials.gov/study/NCT06935409","registryValue":"122 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"nct04145622","kind":"trial","name":"Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors","route":"/trials/nct04145622/","field":"enrolled","current":"250","proposed":"247","reason":"ClinicalTrials.gov actual enrolment is 247","source":"https://clinicaltrials.gov/study/NCT04145622","registryValue":"247 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"nct01872260","kind":"trial","name":"Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer","route":"/trials/nct01872260/","field":"enrolled","current":"255","proposed":"259","reason":"ClinicalTrials.gov actual enrolment is 259","source":"https://clinicaltrials.gov/study/NCT01872260","registryValue":"259 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"nct05673057","kind":"trial","name":"Study of MP0533 in Patients Acute Myeloid Leukemia or Myelodysplastic Syndrome","route":"/trials/nct05673057/","field":"phase","current":"1/2","proposed":"1","reason":"ClinicalTrials.gov lists phases PHASE1","source":"https://clinicaltrials.gov/study/NCT05673057","registryValue":"PHASE1","proposedOn":"2026-10-26"},{"id":"nct05673057","kind":"trial","name":"Study of MP0533 in Patients Acute Myeloid Leukemia or Myelodysplastic Syndrome","route":"/trials/nct05673057/","field":"enrolled","current":"249","proposed":"80","reason":"ClinicalTrials.gov actual enrolment is 80","source":"https://clinicaltrials.gov/study/NCT05673057","registryValue":"80 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"nct06619236","kind":"trial","name":"Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer","route":"/trials/nct06619236/","field":"enrolled","current":"530","proposed":"584","reason":"ClinicalTrials.gov actual enrolment is 584","source":"https://clinicaltrials.gov/study/NCT06619236","registryValue":"584 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"nsclc-2","kind":"trial","name":"Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)","route":"/trials/nsclc-2/","field":"enrolled","current":"840","proposed":"167","reason":"ClinicalTrials.gov actual enrolment is 167","source":"https://clinicaltrials.gov/study/NCT06236438","registryValue":"167 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"nct06909877","kind":"trial","name":"Study to Evaluate Efficacy and Safety of HH2853 in Relapsed/Refractory Peripheral T-cell Lymphoma","route":"/trials/nct06909877/","field":"status","current":"recruiting","proposed":"active","reason":"Primary completion date 2025-10-31 has passed (actual) and the registry status is RECRUITING","source":"https://clinicaltrials.gov/study/NCT06909877","registryValue":"RECRUITING; primary completion 2025-10-31","proposedOn":"2026-10-26"},{"id":"nct04557449","kind":"trial","name":"Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors","route":"/trials/nct04557449/","field":"phase","current":"2","proposed":"1/2","reason":"ClinicalTrials.gov lists phases PHASE1, PHASE2","source":"https://clinicaltrials.gov/study/NCT04557449","registryValue":"PHASE1/PHASE2","proposedOn":"2026-10-26"},{"id":"nct04626479","kind":"trial","name":"Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)","route":"/trials/nct04626479/","field":"enrolled","current":"400","proposed":"393","reason":"ClinicalTrials.gov actual enrolment is 393","source":"https://clinicaltrials.gov/study/NCT04626479","registryValue":"393 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"nct04626518","kind":"trial","name":"Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)","route":"/trials/nct04626518/","field":"enrolled","current":"370","proposed":"263","reason":"ClinicalTrials.gov actual enrolment is 263","source":"https://clinicaltrials.gov/study/NCT04626518","registryValue":"263 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"summit-lung","kind":"trial","name":"SUMMIT (lung health check study)","route":"/trials/summit-lung/","field":"enrolled","current":"12773","proposed":"13035","reason":"ClinicalTrials.gov actual enrolment is 13035","source":"https://clinicaltrials.gov/study/NCT03934866","registryValue":"13035 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"nct05218889","kind":"trial","name":"Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer","route":"/trials/nct05218889/","field":"status","current":"recruiting","proposed":"active","reason":"Primary completion date 2024-12-16 has passed (actual) and the registry status is RECRUITING","source":"https://clinicaltrials.gov/study/NCT05218889","registryValue":"RECRUITING; primary completion 2024-12-16","proposedOn":"2026-10-26"},{"id":"swog-9346","kind":"trial","name":"SWOG 9346 (intermittent androgen deprivation)","route":"/trials/swog-9346/","field":"enrolled","current":"1535","proposed":"3040","reason":"ClinicalTrials.gov actual enrolment is 3040","source":"https://clinicaltrials.gov/study/NCT00002651","registryValue":"3040 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"swog-s0421-atrasentan","kind":"trial","name":"SWOG S0421","route":"/trials/swog-s0421-atrasentan/","field":"enrolled","current":"994","proposed":"1038","reason":"ClinicalTrials.gov actual enrolment is 1038","source":"https://clinicaltrials.gov/study/NCT00134056","registryValue":"1038 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"talapro-2","kind":"trial","name":"TALAPRO-2","route":"/trials/talapro-2/","field":"enrolled","current":"805","proposed":"1054","reason":"ClinicalTrials.gov actual enrolment is 1054","source":"https://clinicaltrials.gov/study/NCT03395197","registryValue":"1054 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"targit-a","kind":"trial","name":"TARGIT-A (targeted intraoperative radiotherapy)","route":"/trials/targit-a/","field":"enrolled","current":"2298","proposed":"3451","reason":"ClinicalTrials.gov actual enrolment is 3451","source":"https://clinicaltrials.gov/study/NCT00983684","registryValue":"3451 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"nct05343013","kind":"trial","name":"TAS-102 With or Without Celecoxib in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy","route":"/trials/nct05343013/","field":"enrolled","current":"25","proposed":"30","reason":"ClinicalTrials.gov actual enrolment is 30","source":"https://clinicaltrials.gov/study/NCT05343013","registryValue":"30 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"nct04214262","kind":"trial","name":"Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer","route":"/trials/nct04214262/","field":"enrolled","current":"415","proposed":"417","reason":"ClinicalTrials.gov actual enrolment is 417","source":"https://clinicaltrials.gov/study/NCT04214262","registryValue":"417 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"nct05555888","kind":"trial","name":"The Combination of Immunotherapy and Neoadjuvant Short-course Radiotherapy in Early Rectal Cancer","route":"/trials/nct05555888/","field":"status","current":"recruiting","proposed":"active","reason":"Primary completion date 2024-03-12 has passed (actual) and the registry status is RECRUITING","source":"https://clinicaltrials.gov/study/NCT05555888","registryValue":"RECRUITING; primary completion 2024-03-12","proposedOn":"2026-10-26"},{"id":"nct05624138","kind":"trial","name":"The Possible Protective Role of Ketotifen Against Oxaliplatin Induced Peripheral Neuropathy","route":"/trials/nct05624138/","field":"status","current":"recruiting","proposed":"active","reason":"Primary completion date 2024-04-04 has passed (actual) and the registry status is RECRUITING","source":"https://clinicaltrials.gov/study/NCT05624138","registryValue":"RECRUITING; primary completion 2024-04-04","proposedOn":"2026-10-26"},{"id":"thor","kind":"trial","name":"THOR","route":"/trials/thor/","field":"enrolled","current":"266","proposed":"629","reason":"ClinicalTrials.gov actual enrolment is 629","source":"https://clinicaltrials.gov/study/NCT03390504","registryValue":"629 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"nct06756269","kind":"trial","name":"To Evaluate the Safety and Immunogenicity of 15-valent HPV Recombinant Vaccine in Chinese People Aged 9-45 Years","route":"/trials/nct06756269/","field":"status","current":"recruiting","proposed":"active","reason":"Primary completion date 2025-10-30 has passed (actual) and the registry status is RECRUITING","source":"https://clinicaltrials.gov/study/NCT06756269","registryValue":"RECRUITING; primary completion 2025-10-30","proposedOn":"2026-10-26"},{"id":"toga","kind":"trial","name":"ToGA","route":"/trials/toga/","field":"enrolled","current":"594","proposed":"584","reason":"ClinicalTrials.gov actual enrolment is 584","source":"https://clinicaltrials.gov/study/NCT01041404","registryValue":"584 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"topaz-1","kind":"trial","name":"TOPAZ-1","route":"/trials/topaz-1/","field":"enrolled","current":"685","proposed":"810","reason":"ClinicalTrials.gov actual enrolment is 810","source":"https://clinicaltrials.gov/study/NCT03875235","registryValue":"810 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"tosca","kind":"trial","name":"TOSCA","route":"/trials/tosca/","field":"enrolled","current":"3759","proposed":"3756","reason":"ClinicalTrials.gov actual enrolment is 3756","source":"https://clinicaltrials.gov/study/NCT00646607","registryValue":"3756 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"tracerx","kind":"trial","name":"TRACERx","route":"/trials/tracerx/","field":"enrolled","current":"421","proposed":"814","reason":"ClinicalTrials.gov actual enrolment is 814","source":"https://clinicaltrials.gov/study/NCT01888601","registryValue":"814 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"train-2","kind":"trial","name":"TRAIN-2","route":"/trials/train-2/","field":"enrolled","current":"438","proposed":"437","reason":"ClinicalTrials.gov actual enrolment is 437","source":"https://clinicaltrials.gov/study/NCT01996267","registryValue":"437 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"transcend","kind":"trial","name":"TRANSCEND","route":"/trials/transcend/","field":"enrolled","current":"120","proposed":"143","reason":"ClinicalTrials.gov actual enrolment is 143","source":"https://clinicaltrials.gov/study/NCT05774756","registryValue":"143 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"transcend-nhl-001","kind":"trial","name":"TRANSCEND NHL 001","route":"/trials/transcend-nhl-001/","field":"enrolled","current":"269","proposed":"387","reason":"ClinicalTrials.gov actual enrolment is 387","source":"https://clinicaltrials.gov/study/NCT02631044","registryValue":"387 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"tribe","kind":"trial","name":"TRIBE","route":"/trials/tribe/","field":"enrolled","current":"508","proposed":"509","reason":"ClinicalTrials.gov actual enrolment is 509","source":"https://clinicaltrials.gov/study/NCT00719797","registryValue":"509 (ACTUAL)","proposedOn":"2026-10-26"},{"id":"nct05948813","kind":"trial","name":"TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases","route":"/trials/nct05948813/","field":"status","current":"recruiting","proposed":"active","reason":"Primary completion date 2025-12-15 has passed (actual) and the registry status is RECRUITING","source":"https://clinicaltrials.gov/study/NCT05948813","registryValue":"RECRUITING; primary completion 2025-12-15","proposedOn":"2026-10-26"},{"id":"ux023t-cl201","kind":"trial","name":"UX023T-CL201","route":"/trials/ux023t-cl201/","field":"enrolled","current":"14","proposed":"17","reason":"ClinicalTrials.gov actual enrolment is 17","source":"https://clinicaltrials.gov/study/NCT02304367","registryValue":"17 (ACTUAL)","proposedOn":"2026-10-26"}]}